Video

Updates in EGFR+ NSCLC, Including Uncommon EGFR Mutations

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer.

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer, as well as advances with uncommon EGFR mutations.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD